Xaliproden in amyotrophic lateral sclerosis: early clinical trials

References

• Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population. Valida- tion of a scoring system and a model for survival prediction. Brain 1995; 118(3): 707–719.
   Google Scholar
• Bensimon G, Lacomblez L, Meininger V, the ALS/riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994; 330: 585–591.
   Google Scholar
• Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V, for the ALS/riluzole Study Group II. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996; 347: 1425–1431.
   Google Scholar
• Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neurons 1998; 1: 623–634.
   Web of Science ®Google Scholar
• Windebrank AJ. Use of growth factors in the treatment of motor neuron diseases. Pathogenesis and therapy of amyo- trophic lateral sclerosis. Adv Neurol 1995; 68: 229–234.
   Google Scholar
• Yuen EC, Mobley WC. Therapeutic applications of neurotrophic factors in disorders of motor neurons and peripheral nerves. Mol Med Today 1995; 1: 278–286.
   PubMedGoogle Scholar
• Lewis ME, Neff NT, Contreras PC et al. Insulin-like growth factor-I: potential for treatment of motor neuronal disorders. Exp Neurol 1993; 124: 73–88.
   Google Scholar
• ALS CNTF treatment study group. A double-blind placebo- controlled clinical trial of subcutaneous human ciliary neuro- trophic factor (rHCNTF) in amyotrophic lateral sclerosis. Neurology 1996; 46: 1244–1249.
   PubMed Web of Science ®Google Scholar
• Lai EC, Felice KJ, Festoff BW et al. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo- controlled study. The North America ALS/IGF-I Study Group. Neurol 1997; 49(6): 1621–1630.
   Google Scholar
• Borasio GD, Robberecht W, Leigh PN et al. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology 1998; 51(2): 583–586.
   PubMed Web of Science ®Google Scholar
• BDNF study group (phase III). A controlled trial of recombinant methionyl human BDNF in ALS:). Neurology 1999; 52: 1427–1433.
   PubMed Web of Science ®Google Scholar
• Miller RG, Bryan WW, Dietz MA et al. Toxicity and tolerability of recombinant human ciliary neurotrophic factor in patients with amyotrophic lateral sclerosis. Neurology 1996; 47(5): 1329–1331.
   Google Scholar
• Miller RG, Petajan JH, Bryan WW et al. A placebo-controlled trial of recombinant human ciliary neurotrophic (rHCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS study group. Ann Neurol 1996; 39: 256–260.
   Google Scholar
• Penn RD, Kroin JS, York MM, Cedarbaum JM. Intrathecal ciliary neurotrophic factor delivery for treatment of amyotrophic lateral sclerosis (phase I trial). Neurosurg 1997; 40: 94–99.
   PubMed Web of Science ®Google Scholar
• Cedarbaum JM, DeStefano PS, Lakings DB, Lindsay RM. Pharmacokinetics and pharmacodynamics of rHCNTF in rodents. Ann Neurol 1996; 39(4): 552–554.
   PubMed Web of Science ®Google Scholar
• Askanas V. Neurotrophic factors and amyotrophic lateral sclerosis. Adv Neurol 1995; 68: 241–244.
   PubMedGoogle Scholar
• Fournier J, Steinberg R, Gauthier T et al. Protective effects of SR57746A in central and peripheral models of neurodegenera- tive disorders in rodents and primates. Neuroscience 1993; 55(3): 629–641.
   Google Scholar
• Fournier J, Keane PE, Ferrara P, Soubrie´ P. SR 57746A: an orally active non-peptide compound with neurotrophic and neuro- protective effects. CNS Drug Rev 1997; 3(2): 148–167.
   Google Scholar
• Fournier J, Boutot G, Keane PE, Maffrand JP, Le Fur G, Soubrie´ P. The non-peptide neuroprotective agents SR 57746A interacts with neurotrophin 3 to induce differenciation in the PC12 cell- line. J Pharm Pharmacol 1998; 50(3): 323–327.
   PubMed Web of Science ®Google Scholar
• Labie C, Lafon C, Marmouget C et al. Effect of the neuro- protective compound SR 57746A on nerve growth factor synthesis in cultured astrocytes from neonatal rat cortex. Br J Pharmacol 1999; 127(1): 139–144.
   Google Scholar
• Bachy A, Steinberg R, Santucci V et al. Biochemical and electrophysiological properties of SR 57746A, a new potent 5HT1A receptor agonist. Fundam Clin Pharmacol 1993; 7(9): 487–497.
   Google Scholar
• Duong F, Warter JM, Poindron P, Passilly P. Effect of non- peptide neurotrophic compound xaliproden on the phenotypic survival of purified mouse motor neurons. Br J Pharmacol 1999; 128(7): 1385–1392.
   PubMed Web of Science ®Google Scholar
• Duong F, Fournier J, Keane PE et al. The effect of the non- peptide neurotrophic compound SR 57746A on the progression of the disease state of the pmn mouse. Br J Pharmacol 1998; 124(4): 811–817.
   Google Scholar
• Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1994; 124(suppl): 96–107.
   Google Scholar
• Raskin A, Schulterbrandt J, Reatig N, McKeon JJ. Replication of factors of psychopathology in interview, ward behaviour and self-report ratings of hospitalised depressives. J Nerv Ment Dis 1969 Jan; 148(1): 87–98.
   PubMed Web of Science ®Google Scholar
• Covi L, Lipman RS, McNair DM, Czerlinsky T. Symptomatic volunteers in multicentre drug trials. Prog Neuropsycho- pharmacol 1979; 3(5-6): 521–33.
   Google Scholar
• Hildebrand M, Seifert W, Reichenberger A. Determination of dextromethorphan metaboliser phenotype in healthy volunteers. Eur J Clin Pharmacol 1989; 36: 315–318.
   PubMed Web of Science ®Google Scholar